Prothena Co. plc (NASDAQ:PRTA - Get Free Report)'s stock price traded up 3.7% during trading on Thursday . The stock traded as high as $23.70 and last traded at $23.67. 91,589 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 785,332 shares. The stock had previously closed at $22.82.
Wall Street Analyst Weigh In
A number of research firms have weighed in on PRTA. Oppenheimer reduced their price objective on Prothena from $98.00 to $80.00 and set an "outperform" rating for the company in a research note on Tuesday, February 20th. StockNews.com downgraded Prothena from a "hold" rating to a "sell" rating in a report on Monday, February 19th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Prothena in a research note on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $90.00 target price on shares of Prothena in a research note on Wednesday, March 13th. Finally, JMP Securities raised their price target on shares of Prothena from $81.00 to $85.00 and gave the company a "market outperform" rating in a research report on Friday, February 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $69.63.
Check Out Our Latest Analysis on Prothena
Prothena Stock Up 2.0 %
The stock's 50-day simple moving average is $26.57 and its two-hundred day simple moving average is $33.95. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -8.31 and a beta of 0.21.
Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.03). Prothena had a negative net margin of 160.91% and a negative return on equity of 24.84%. The company had revenue of $0.32 million during the quarter, compared to analysts' expectations of $2.15 million. During the same period in the prior year, the business posted $0.12 earnings per share. The company's quarterly revenue was down 99.4% compared to the same quarter last year. On average, sell-side analysts forecast that Prothena Co. plc will post -4.87 EPS for the current year.
Insider Transactions at Prothena
In other Prothena news, CAO Karin L. Walker sold 5,000 shares of the firm's stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $34.00, for a total value of $170,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 28.10% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. KBC Group NV purchased a new stake in Prothena in the fourth quarter valued at $34,000. Point72 Middle East FZE purchased a new position in Prothena in the fourth quarter valued at $48,000. PNC Financial Services Group Inc. grew its stake in Prothena by 265.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,544 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,122 shares in the last quarter. Lazard Asset Management LLC grew its position in shares of Prothena by 61.1% during the first quarter. Lazard Asset Management LLC now owns 1,733 shares of the biotechnology company's stock worth $63,000 after buying an additional 657 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Prothena by 99.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,375 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 684 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company's stock.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Recommended Stories
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
